Ferroptosis begins when the balance between oxidative damage and cellular antioxidant protection collapses. Iron imported into tumor cells through transferrin receptor 1 can be converted into reactive forms of Fe²⁺, which participate in Fenton reactions and generate highly damaging hydroxyl radicals. These radicals attack polyunsaturated fatty acids incorporated into phospholipids, initiating lipid peroxidation. As oxidized lipids accumulate, membrane integrity deteriorates until the cell can no longer survive. Prostate cancer cells, particularly aggressive and metastatic populations, may be unusually vulnerable to this process because their growth depends on extensive metabolic activity and altered iron and lipid handling.

Three interconnected systems determine whether a prostate cancer cell resists or undergoes ferroptosis: iron metabolism, lipid metabolism, and antioxidant defense. The glutathione–glutathione peroxidase 4, or GSH–GPX4, system is one of the most important protective mechanisms. GPX4 converts toxic lipid hydroperoxides into less harmful molecules, but it requires glutathione to function. Other protective systems include ferroptosis suppressor protein 1, known as FSP1, which supports membrane protection through coenzyme Q10, and dihydroorotate dehydrogenase, or DHODH, which helps defend mitochondrial membranes. A separate tetrahydrobiopterin-dependent pathway can also limit lipid oxidation. Ferroptosis therefore reflects a biochemical contest between the production of oxidative damage and the tumor cell’s ability to neutralize it.

Lipid composition is a particularly important determinant of sensitivity. The enzyme ACSL4 promotes the incorporation of polyunsaturated fatty acids into membrane phospholipids, creating substrates that are readily oxidized and increasing ferroptotic vulnerability. By contrast, stearoyl-CoA desaturase 1, or SCD1, produces monounsaturated fatty acids that are less prone to oxidation and can stabilize cellular membranes. Other regulators, including phospholipase A2G4A, prostaglandin E2, and the BH4–coenzyme Q10 antioxidant network, further shape this response. These relationships suggest that the metabolic profile of an individual tumor may be as important as its genetic profile when determining whether ferroptosis-based treatment will work.

The review also describes how major prostate cancer signaling pathways influence this metabolic balance. Loss of the tumor suppressor PTEN can activate the PI3K–AKT–mTOR pathway, stimulating lipid production through SREBP1 and SCD1 and thereby helping cancer cells avoid ferroptosis. The Hippo pathway and its transcriptional regulator YAP can either promote or suppress ferroptosis depending on the cellular context. The tumor suppressor p53 likewise has a dual role, capable of enhancing ferroptosis in some settings while supporting resistance in others. Such complexity may explain why a single ferroptosis-inducing drug is unlikely to be effective in every prostate tumor.

The immune system adds another layer of control. Activated CD8-positive T cells release interferon-gamma, which can reduce expression of SLC7A11, a transporter required for importing cystine and maintaining glutathione production. By weakening this antioxidant supply line, T cells may make tumor cells more susceptible to lipid peroxidation. Immune checkpoint inhibitors such as PD-1 blockers could intensify this interaction. At the same time, M2-polarized tumor-associated macrophages may protect cancer cells through the LXR-alpha/SCD1 pathway. The authors describe a potential “immune–ferroptosis cycle” in which ferroptotic tumor cells release danger signals that stimulate anti-tumor immunity, while immune activity further increases the tumor’s sensitivity to ferroptosis.

These mechanisms point toward a range of possible biomarkers. Levels of TFR1, ACSL4, SCD1, Nrf2, SLC7A11, GPX4, and DECR1, together with activation of the PI3K–AKT–mTOR pathway, could provide clues about ferroptosis susceptibility. High levels of GPX4 or SLC7A11 may indicate that a tumor has built strong antioxidant defenses and is likely to resist treatment. Conversely, elevated ACSL4 or increased intracellular iron could signal a more vulnerable metabolic state. The review proposes combining genomic, transcriptomic, proteomic, and metabolomic measurements rather than relying on a single marker. Such integrated profiles could eventually guide treatment selection in CRPC, where existing therapies often lose effectiveness.

Several experimental drugs directly or indirectly attack the antioxidant machinery. GPX4 inhibitors such as RSL3, ML162, ML210, and FIN56 can permit lipid peroxides to accumulate, while compounds including erastin, sulfasalazine, sorafenib, and buthionine sulfoximine reduce glutathione availability and indirectly disable GPX4. Other agents, including dihydroartemisinin, artemisinin, and PX-12, increase oxidative stress through iron-dependent reactions or effects on redox signaling. In laboratory and animal models, these approaches have shown stronger effects when combined with iron supplementation or with treatments that increase lipid oxidation. Ferroptosis inducers have also displayed preclinical synergy with anti-androgen drugs such as enzalutamide and darolutamide, as well as with cisplatin, docetaxel, mTOR inhibitors, PHGDH inhibitors, and immunotherapies.

Drug-delivery technology may help turn these experimental findings into more selective treatments. The review highlights nanoparticles engineered to recognize prostate-specific membrane antigen and deliver iron together with RSL3 directly to tumor cells. Other platforms use magnetic lipid nanoparticles to transport DECR1-targeting RNA molecules, or manganese sulfide systems that generate reactive oxygen species inside tumors. By concentrating ferroptosis-inducing activity at the cancer site, these platforms could reduce damage to healthy tissues and address the systemic toxicity that has limited many oxidative therapies. However, the field remains largely preclinical. Prostate tumors can adapt by increasing GPX4, SLC7A11, FSP1, or Nrf2, rewiring metabolism, and exploiting hypoxic regions that suppress oxidative reactions. The review therefore calls for mechanism-based biomarkers, lipidomics, ferroptosis imaging, improved delivery systems, and carefully designed clinical trials. Ferroptosis is not yet an established treatment, but its ability to exploit the metabolic weaknesses of resistant prostate cancer makes it one of the most closely watched emerging strategies in precision oncology.

Subject of Research: Ferroptosis-based therapy and precision medicine strategies for advanced and castration-resistant prostate cancer.

Article Title: Ferroptosis and prostate cancer: A translational path from molecular mechanisms to precision therapy

Web References: https://doi.org/10.1016/j.gendis.2025.101967

References: Yixiang Huang, Yuanxin Ma, Jiachen He, Tanjing Song, “Ferroptosis and prostate cancer: A translational path from molecular mechanisms to precision therapy,” Genes & Diseases, Volume 13, Issue 5, 2026, Article 101967.

Image Credits: Genes & Diseases

Keywords: Ferroptosis, prostate cancer, castration-resistant prostate cancer, lipid peroxidation, GPX4, ACSL4, SLC7A11, iron metabolism, immunotherapy, precision medicine

Hepatocellular carcinoma, the predominant form of primary liver cancer, continues to pose substantial challenges in oncology due to its poor prognosis and limited treatment options. One promising therapeutic strategy that has emerged over recent years is the induction of ferroptosis, a unique form of cell death distinguished from apoptosis and necrosis by its iron-dependence and lipid peroxidation signatures. However, cancer cells have evolved multiple resistance mechanisms to avoid ferroptosis, complicating therapeutic efforts. The current research sheds light on one such mechanism, centered around metabolic adaptations involving methionine metabolism.

Methionine is not merely an essential amino acid; it is a pivotal player in cellular methylation processes, redox homeostasis, and polyamine synthesis, all of which are crucial for cell survival and proliferation. The study reveals that HNF4α modulates methionine metabolism, thereby enhancing the capacity of HCC cells to withstand the oxidative stress that triggers ferroptosis. The activation of methionine pathways appears to bolster antioxidant defenses, buffering cells against lipid peroxidation and preventing the lethal cascade characteristic of ferroptosis.

Through a series of sophisticated molecular biology techniques, the authors demonstrated that HNF4α upregulates key enzymes involved in methionine metabolism. These enzymes facilitate the conversion of methionine into protective metabolites such as glutathione, a major cellular antioxidant. The increased glutathione synthesis enhances the scavenging of reactive oxygen species (ROS) and peroxidized lipids, effectively shielding cancer cells from ferroptotic death. This metabolic reprogramming not only confers resistance but also challenges current attempts to sensitize HCC to ferroptosis-inducing therapies.

Furthermore, the study investigated the implications of silencing HNF4α expression in HCC cell lines. Remarkably, knockdown of HNF4α led to a pronounced decrease in methionine metabolism-related enzyme levels, accompanied by heightened susceptibility to ferroptosis. These findings were substantiated by in vivo tumor models, where HNF4α inhibition reduced tumor growth and increased ferroptotic markers, underscoring the therapeutic potential of targeting this axis.

The interplay between transcriptional regulation and metabolic adaptation highlights the complexity of cancer cell survival strategies. HNF4α, traditionally recognized for its role in liver development and function, has now been implicated as a master regulator of metabolic pathways that dictate ferroptosis sensitivity. This dual functionality positions HNF4α as a critical node intersecting oncogenic signaling and metabolic resilience, offering a potentially exploitable vulnerability.

Importantly, the activation of methionine metabolism through HNF4α may also impact other metabolic circuits, including transmethylation and transsulfuration pathways. These interconnected networks are vital for maintaining redox balance and cellular integrity under stress conditions. The study suggests that disrupting methionine metabolism could create metabolic bottlenecks, sensitizing HCC cells not only to ferroptosis but perhaps to other stress-related vulnerabilities as well.

The clinical ramifications of these findings are profound. Current therapeutic landscapes for HCC rely heavily on surgical resection, locoregional therapies, and systemic agents such as checkpoint inhibitors and kinase inhibitors. The identification of metabolic adaptations conferring ferroptosis resistance necessitates the development of combination strategies that can concurrently target metabolic enzymes and ferroptotic pathways, thereby circumventing resistance mechanisms.

Moreover, the study advances the possibility of using HNF4α expression or methionine metabolic activity as biomarkers to predict the responsiveness of HCC patients to ferroptosis-inducing agents. Personalized therapy regimens tailored to the metabolic profile of tumors could significantly enhance efficacy and reduce unintended toxicity, a critical consideration in liver cancer management.

The mechanistic insights afforded by this research also open prospects for the design of innovative small-molecule inhibitors aimed at selectively modulating methionine metabolism enzymes. Such pharmacological interventions could restore ferroptosis sensitivity and promote tumor cell death, either as stand-alone treatments or as adjuvants enhancing existing therapeutic modalities.

Beyond the scope of hepatocellular carcinoma, these findings underscore the broader significance of metabolic reprogramming in cancer biology. The capacity of tumors to adapt their metabolism to environmental and therapeutic pressures is a hallmark of malignancy, and disarming these adaptive networks remains a grand challenge. This study exemplifies how deep molecular investigations can reveal critical nodes amenable to intervention.

In summary, the activation of methionine metabolism mediated by HNF4α emerges as a key axis conferring ferroptosis resistance in HCC. By orchestrating metabolic pathways that bolster antioxidant defenses, HNF4α enables cancer cells to survive lethal oxidative insults. Targeting this metabolic adaptation holds promise for overcoming therapeutic resistance and improving outcomes for patients afflicted with liver cancer. As research continues to unravel the metabolic underpinnings of tumor survival, such discoveries propel the field toward more effective and precise cancer therapies.

This work not only expands the conceptual framework of ferroptosis resistance but also lays the groundwork for future clinical translation. The challenge remains to harness these mechanistic insights into practical interventions that can be brought to the bedside. Given the lethality of HCC and the current gaps in treatment efficacy, targeting the HNF4α-methionine metabolism axis represents a beacon of hope for novel, metabolically informed therapeutic strategies.

With the ongoing advances in cancer metabolism research and ferroptosis biology, it is plausible to envision a future where metabolic vulnerabilities are routinely exploited to eradicate resilient tumor cells. The contribution of Zhou, Li, Wang, and colleagues marks a significant milestone on this challenging yet promising journey, illuminating the path toward metabolic therapy as a cornerstone of cancer treatment.

Subject of Research:
Activation of methionine metabolism mediated by HNF4α and its role in conferring ferroptosis resistance in hepatocellular carcinoma.

Article Title:
Activation of methionine metabolism mediated by HNF4α confers ferroptosis resistance in hepatocellular carcinoma.

Article References:
Zhou, X., Li, Z., Wang, L. et al. Activation of methionine metabolism mediated by HNF4α confers ferroptosis resistance in hepatocellular carcinoma. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03165-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03165-0